8-K: Adaptive Biotechnologies Reports Strong 2025 Growth

Adaptive Biotechnologies announced preliminary, unaudited Q4 and full year 2025 results, showcasing significant revenue and clonoSEQ test volume increases, and outlining a path to company-wide profitability by late 2026.

Summary

• Total revenue for Q4 2025 was approximately $72 million, a 51% increase over Q4 2024.
• Total revenue for full year 2025 reached approximately $277 million, a 55% increase over full year 2024.
• MRD revenue for Q4 2025 was approximately $62 million, up 54% from Q4 2024, and for full year 2025 was approximately $212 million, up 46% from full year 2024.
• Excluding MRD regulatory milestone revenue, full year 2025 MRD revenue grew 45% over 2024.
• clonoSEQ test volume increased 43% to approximately 30,000 tests in Q4 2025 compared to Q4 2024.
• Full year 2025 clonoSEQ test volume was approximately 105,600 tests, a 39% increase over full year 2024.
• Cash, cash equivalents, and marketable securities stood at approximately $227 million as of December 31, 2025, excluding Digital Biotechnologies, Inc. cash.
• The company expects its fourth quarter and full year 2025 net loss to decrease compared to comparable periods in 2024.
• Adaptive aims to achieve positive adjusted EBITDA and positive free cash flow for the entire company by the end of 2026.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results with significant revenue and test volume growth, a healthy cash position, and a clear strategic outlook towards company-wide profitability by the end of 2026. While the results are unaudited, the consistent positive trends across key metrics and management's confident guidance indicate a very positive sentiment.

Positives

• Strong total revenue growth of 55% for full year 2025 to $277 million.
• Significant MRD revenue growth of 46% for full year 2025 to $212 million, driven by clonoSEQ adoption.
• Robust clonoSEQ test volume increase of 39% for full year 2025, reaching approximately 105,600 tests.
• Healthy cash position with approximately $227 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Anticipated decrease in net loss for both Q4 and full year 2025 compared to 2024.
• Clear strategic path to achieve positive adjusted EBITDA and positive free cash flow for the entire company by the end of 2026.
• Strong gross margins for MRD sequencing, achieving 65% in Q2 2025 and 70% in Q3 2025, with a target of >70% for FY 2026.
• Expansion of clonoSEQ's market position through blood-based testing, community presence, data generation, guideline updates, and EMR integrations.
• Successful closure of two data agreements with Pfizer and completion of a pre-clinical package for a TCR-depleting antibody in Ankylosing Spondylitis within the Immune Medicine segment.

Negatives

• Preliminary financial results are unaudited and subject to change, which introduces a degree of uncertainty.
• Specific estimated expenses for Q4 and full year 2025 were not disclosed, although a decrease in net loss is expected.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied.
• Preliminary and unaudited financial results for Q4 and full year 2025 are inherently uncertain and subject to change as the company completes its customary year-end close, prepares financial statements, and completes the audit. Final results may differ materially from these estimates.
• The company does not undertake any obligation to update forward-looking statements for any reason, except as required by law.

Future Outlook

Adaptive Biotechnologies anticipates continued strong growth in its Minimal Residual Disease (MRD) business, with clinical volume growth exceeding 30% year-over-year and an average selling price of approximately $1,400 per US clinical test in fiscal year 2026. The company expects MRD sequencing gross margins to be over 70% and projects mid-single digit millions in MRD milestone revenue for 2026. Management is focused on extending leadership in MRD testing, sustaining clonoSEQ volume and ASP growth, and expanding MRD profitability. The company also aims to advance its immune data play, including securing data partnerships and out-licensing pre-clinical antibody data. A key overarching goal is to achieve positive adjusted EBITDA and positive free cash flow for the entire company by the end of 2026.

Management Comments

• "2025 was a pivotal year for Adaptive, marked by accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption."
• "As we look ahead to 2026, we are well-positioned to extend our leadership in MRD testing, sustain strong clonoSEQ volume and ASP growth, and further expand MRD profitability."
• Management expects fourth quarter and full year 2025 net loss to decrease compared to comparable periods in 2024.

Industry Context

Adaptive Biotechnologies operates in the rapidly evolving biotechnology and diagnostics sector, specifically leveraging the adaptive immune system for disease diagnosis and treatment. The strong growth in its Minimal Residual Disease (MRD) segment, particularly with clonoSEQ, indicates increasing adoption of advanced molecular diagnostics in oncology, especially for blood cancers. The focus on expanding into new indications like CLL and DLBCL, alongside existing strengths in MM and ALL, aligns with broader industry trends towards personalized medicine and more precise disease monitoring. The company's efforts in Immune Medicine, including AI models for TCR-antigen binding, position it within the cutting-edge of immune-driven drug discovery and diagnostics, a highly competitive and innovative area.

Comparison to Industry Standards

• The company's clonoSEQ assay is FDA cleared for MM, ALL, and CLL, and has broad clinical coverage with 300 million covered lives in ALL and MM, 265 million in CLL, and 90 million in DLBCL, positioning it as a leading solution in the MRD testing space.
• The regulatory endorsement by the FDA ODAC of MRD as a primary endpoint in Multiple Myeloma clinical trials highlights clonoSEQ's gold standard position and its increasing relevance in clinical development, a benchmark for advanced diagnostic tools.
• The company's achievement of 65% and 70% gross margins for MRD sequencing in Q2 and Q3 2025, respectively, with a target of over 70% for FY 2026, demonstrates strong operational efficiency compared to many early-stage biotechnology companies.
• The company's goal to achieve positive adjusted EBITDA and positive free cash flow by the end of 2026 is a significant milestone, indicating a move towards financial self-sufficiency, which is often a challenge for growth-stage biotech firms.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong revenue growth, increasing test volumes, improved financial outlook, and a clear path to profitability, potentially leading to increased share value.
• Patients: Positive impact through expanded access to clonoSEQ testing, including blood-based options and broader EMR integration, leading to more precise disease monitoring and potentially better treatment decisions for cancer and autoimmune disorders.
• Employees: Positive impact from a growing company with clear strategic goals, potentially leading to job security and opportunities for professional development.
• Biopharmaceutical Partners: Continued collaboration and potential for new partnerships based on the company's robust immune medicine platform and data monetization opportunities.
• Creditors: Positive impact from improved financial health and a clear path to profitability, enhancing the company's creditworthiness.

Next Steps

• Release complete fourth quarter and full year 2025 financial results during an earnings call in February 2026.
• Extend TCR-antigen data for AI/ML models and secure data partnerships within the Immune Medicine segment.
• Out-license or publish antibody pre-clinical data.
• File for CLL recurrence monitoring approval in 2026.
• Pursue DLBCL/MM recurrence monitoring approval post-2026.
• Continue to expand clonoSEQ utilization through blood-based testing, community presence, data generation, guideline updates, and EMR integrations.
• Work towards achieving positive adjusted EBITDA and positive free cash flow for the entire company by the end of 2026.

Key Dates

Recommendation

Adaptive Biotechnologies has reported exceptionally strong preliminary financial results for Q4 and full year 2025, demonstrating significant revenue and clonoSEQ test volume growth. The company maintains a healthy cash position and has outlined a clear, actionable strategy to achieve company-wide positive adjusted EBITDA and free cash flow by the end of 2026. The expansion of clonoSEQ's market penetration through strategic initiatives like blood-based testing, EMR integration, and guideline updates, coupled with the promising advancements in its Immune Medicine segment, positions the company for sustained long-term growth. The strong operational performance, coupled with a positive outlook and clear milestones, makes this an attractive investment opportunity.

Keywords

Adaptive Biotechnologies, ADPT, SEC Filing, 8-K, Financial Results, Q4 2025, Full Year 2025, Revenue Growth, MRD, clonoSEQ, Biotechnology, Immune Medicine, Diagnostics, Oncology, Cash Position, EBITDA, Free Cash Flow, Investor Presentation